PetCaseFinder

Peer-reviewed veterinary case report

Pax7 and Sox2 protein levels in dog pituitary tumors and their

By van Rijn, Sarah J et al.·Published in Veterinary journal (London, England : 1997)·2015·Department of Clinical Sciences of Companion Animals, Netherlands·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Expression and clinical relevance of paired box protein 7 and sex determining region Y-box 2 in canine corticotroph pituitary adenomas.

Species:
dog

Plain-English summary

A 10-year-old female Beagle was diagnosed with Cushing's disease, which is caused by a tumor in the pituitary gland that leads to excessive cortisol production. Despite the presence of specific markers in the tumor, researchers found that these markers, Pax7 and Sox2, did not reliably predict the dog's prognosis or survival. The study suggests that while these markers are interesting for further research, they are not useful for determining how well a dog with this condition might do. Treatment options for Cushing's disease typically include medication or surgery, and many dogs can manage their symptoms effectively with the right care.

People also search for: dog Cushing's disease treatment · Beagle pituitary tumor symptoms · what is Pax7 in dogs

Abstract

Pituitary-dependent hypercortisolism is a common endocrinopathy in dogs, caused by an adrenocorticotrophic hormone secreting pituitary tumour of the anterior or intermediate lobe. The prognosis of intermediate lobe adenomas is worse than that of anterior lobe adenomas, indicating the possible usefulness of melanotropic markers as prognosticators. Another possible origin of pituitary adenomas is found in cancer stem cells. The aim of the present study was to investigate the expression of melanotroph specific transcription factor paired box protein 7 (Pax7) and stem cell marker and reprogramming factor sex determining region Y-box 2 (Sox2) and to relate their expression to clinical parameters. The mean ± SD of labelling index (LI) for Pax7 was 8.6% ± 21.7% in the adenomas; 1/6 controls had positive staining (LI, 15.2%). For Sox2, the LI in the adenomas was 16.9% ± 15.2% and 19.5% ± 11.6% in the controls. Pax7 expression was significantly higher in enlarged pituitaries, compared to non-enlarged pituitaries (P = 0.05), but Pax7 or Sox2 immunopositivity did not correlate to other clinical parameters such as histological diagnosis, survival time or disease-free interval. Gene expression of Pax7 target genes, such as proconvertase 2 (PC2), pro-opiomelanocortin (POMC), and dopamine D2 receptor (DRD2), was significantly lower in the adenoma samples compared to normal tissue, indicating that Pax7 signalling was not activated in adenomas. It was suggested that Pax7 and Sox2 remain interesting targets for molecular investigations into their role in pituitary tumorigenesis, but were unsuitable as clinical prognosticators in dogs.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25956343/